A Phase 2 interventional study of Vonafexor and Placebo in Non-alcoholic Steatohepatitis, sponsored by Enyo Pharma. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Enyo Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 135th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 273rd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Enyo Pharma is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Enyo Pharma has 2 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effects of EYP001a (Vonafexor) with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH
This is a 2-part, randomized, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of Vonafexor in patients with NASH who likely have stage F2 to F3 fibrosis at approximately 50 global clinical sites. Overall, approximately 114 eligible patients will be enrolled: 24 patients in Part A (Safety Run-in Cohort), followed by 90 patients in Part B.
In Part A, 24 patients will be randomized on Day 1 to 1 of 4 parallel treatment groups: 100 mg Vonafexor twice daily (BID), 200 mg Vonafexor once daily (QD), 400 mg Vonafexor QD, or placebo BID. In Part B, 90 patients will be randomized on Day 1 to 1 of 3 parallel treatment groups: 100 mg Vonafexor QD, 200 mg Vonafexor QD, or placebo QD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dose twice daily for 12 weeks (84 days)
Drug: Vonafexor
Oral dose once daily for 12 weeks (84 days)
Drug: Vonafexor
Oral dose once daily for 12 weeks (84 days)
Drug: Vonafexor
Oral dose twice daily for 12 weeks (84 days)
Other: Placebo
Oral dose once daily for 12 weeks (84 days)
Drug: Vonafexor
Oral tablets
Oral tablets
Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.
Time frame: 12 weeks
Analysis of Change From Baseline in Glomerular Filtration rate_Part B
Time frame: 12 weeks
Analysis of Percent Change (Relative) From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.
Time frame: 12 weeks
Analysis of Change From Baseline in Corrected T1 (CT1)
Time frame: 12 weeks
Analysis of Change From Baseline in Alanine Aminotransferase (ALT)
Time frame: 12 weeks
Analysis of Change From Baseline in Gamma Glutamyltranspeptidase (GT)
Time frame: 12 weeks
Analysis of Change From Baseline in Body Weight
Time frame: 12 weeks
Analysis of Change From Baseline in Waist Circumference
Time frame: 12 weeks
Analysis of Change From Baseline in Waist to Hip ratio_Part B
Time frame: 12 weeks
Analysis of Change From Baseline in Glomerular Filtration rate_Part A
For Part A, as per ICH, analysis were performed as defined in the SAP: data from the 3 vonafexor treatment groups were pooled and compared with the placebo group.
Time frame: 12 weeks
| Milestone | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B |
|---|---|---|---|---|---|
| Started | 7 | 17 | 32 | 31 | 33 |
| Completed | 5 | 7 | 32 | 25 | 23 |
| Not completed | 2 | 10 | 0 | 6 | 10 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 | 2 |
| Withdrew: Stopping rules | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 9 | 0 | 3 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 3 |
The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.
| Percentage of liver fat change | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|---|---|---|
| Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) | -2.3 (-4.0 to -0.6) | -6.3 (-8.1 to -4.5) | -5.4 (-7.2 to -3.6) | 3.9 (-2.5 to 10.4) | -4.7 (-8.5 to 0.9) |
| mL/min/1.73m2 | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B |
|---|---|---|---|
| Analysis of Change From Baseline in Glomerular Filtration rate_Part B | -2.7 (-6.6 to 1.2) | 6.2 (1.9 to 10.2) | 3.2 (-1.2 to 7.7) |
The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level.
| Percent change | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|---|---|---|
| Analysis of Percent Change (Relative) From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) | -10.5 (-19.0 to -2.0) | -30.4 (-39.4 to -21.3) | -25.3 (-34.3 to -16.2) | 11.7 (-28.5 to 51.9) | -25.0 (-48.4 to -1.5) |
| msec | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|---|---|---|
| Analysis of Change From Baseline in Corrected T1 (CT1) | -9.9 (-38.5 to 18.7) | -80.2 (-110.6 to -49.8) | -71.8 (-100.4 to -43.2) | 35.0 (-27.0 to 97.0) | -58.2 (-98.7 to -17.8) |
| U/L | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|---|---|---|
| Analysis of Change From Baseline in Alanine Aminotransferase (ALT) | -11.7 (-18.9 to -4.6) | -16.3 (-24.1 to -8.4) | -7.5 (-15.3 to 0.4) | -4.1 (-27.5 to 19.3) | 17.7 (1.9 to 33.5) |
| U/L | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|---|---|---|
| Analysis of Change From Baseline in Gamma Glutamyltranspeptidase (GT) | -3.9 (-9.9 to 2.2) | -40.6 (-47.1 to -34.0) | -34.1 (-40.6 to -27.7) | 3.7 (-7.8 to 15.2) | -25.2 (-34.2 to -16.3) |
| kg | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|---|---|---|
| Analysis of Change From Baseline in Body Weight | -0.1 (-1.0 to 0.9) | -1.7 (-2.7 to -0.7) | -2.5 (-3.5 to -1.5) | 1.2 (-1.0 to 3.4) | -2.2 (-3.7 to -0.7) |
| cm | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|---|---|---|
| Analysis of Change From Baseline in Waist Circumference | 0.1 (-1.2 to 1.3) | -1.2 (-2.6 to 0.1) | -2.2 (-3.6 to -0.9) | -1.8 (-5.0 to 1.4) | -2.9 (-5.0 to -0.7) |
| ratio | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B |
|---|---|---|---|
| Analysis of Change From Baseline in Waist to Hip ratio_Part B | 0.014 (0.001 to 0.026) | -0.017 (-0.031 to -0.003) | -0.010 (-0.024 to 0.004) |
For Part A, as per ICH, analysis were performed as defined in the SAP: data from the 3 vonafexor treatment groups were pooled and compared with the placebo group.
| mL/min/1.73m^2 | Placebo Part A | Vonafexor Pooled Part A |
|---|---|---|
| Analysis of Change From Baseline in Glomerular Filtration rate_Part A | -4 ± 18.4 | -11.3 ± 12.5 |
Collected over After dose the first dose of study drug until D96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Part A | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Vonafexor 100 mg BID Part A | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Vonafexor 200 mg QD Part A | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Vonafexor 400 mg QD Part A | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Placebo Part B | 0/32 (0%) | 1/32 (3.1%) | 22/32 (68.8%) |
| Vonafexor 100 mg QD Part B | 0/31 (0%) | 1/31 (3.2%) | 25/31 (80.6%) |
| Vonafexor 200 mg QD Part B | 0/33 (0%) | 2/33 (6.1%) | 30/33 (90.9%) |
| Event | Placebo Part A | Vonafexor 100 mg BID Part A | Vonafexor 200 mg QD Part A | Vonafexor 400 mg QD Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B |
|---|---|---|---|---|---|---|---|
| Angina instableCardiac disorders | 0/7 | 0/6 | 0/5 | 0/6 | 0/32 | 1/31 | 0/33 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/7 | 0/6 | 0/5 | 0/6 | 0/32 | 1/31 | 0/33 |
| VertigoEar and labyrinth disorders | 0/7 | 0/6 | 0/5 | 0/6 | 1/32 | 0/31 | 0/33 |
| Transaminases increasedInvestigations | 0/7 | 0/6 | 0/5 | 0/6 | 0/32 | 0/31 | 1/33 |
| COVID-19Infections and infestations | 0/7 | 0/6 | 0/5 | 0/6 | 0/32 | 0/31 | 1/33 |
| Event | Placebo Part A | Vonafexor 100 mg BID Part A | Vonafexor 200 mg QD Part A | Vonafexor 400 mg QD Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B |
|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 0/7 | 5/6 | 4/5 | 6/6 | 4/32 | 19/31 | 22/33 |
| NauseaGastrointestinal disorders | 0/7 | 0/6 | 0/5 | 2/6 | 2/32 | 0/31 | 5/33 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 0/6 | 1/5 | 0/6 | 0/32 | 0/31 | 0/33 |
| Adverse drug reactionGeneral disorders | 0/7 | 0/6 | 1/5 | 0/6 | 0/32 | 0/31 | 0/33 |
| AnxietyPsychiatric disorders | 0/7 | 0/6 | 1/5 | 0/6 | 0/32 | 0/31 | 0/33 |
| Abdominal painGastrointestinal disorders | 0/7 | 0/6 | 1/5 | 0/6 | 0/32 | 0/31 | 1/33 |
| Abdominal rigidityGastrointestinal disorders | 0/7 | 0/6 | 1/5 | 0/6 | 0/32 | 0/31 | 1/33 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/7 | 0/6 | 1/5 | 0/6 | 0/32 | 1/31 | 0/33 |
| FatigueGeneral disorders | 1/7 | 1/6 | 0/5 | 0/6 | 1/32 | 0/31 | 0/33 |
| AgitationPsychiatric disorders | 0/7 | 1/6 | 0/5 | 0/6 | 0/32 | 0/31 | 0/33 |
For Part A, data from the 3 vonafexor treatment groups were pooled and summarized. Due to the small number of subjects by treatment group in Part A, and as the Study EYP001 202 Part A PK results between groups were found to be nonlinear with similar exposure for the vonafexor 200 mg QD and vonafexor 400 mg QD groups, only the pooled vonafexor treatment group were compared with the placebo group.
| Age, Continuous(years) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| Age Part A | 48.7 ± 18.4 | 56.1 ± 8.9 | — | — | — | 54.0 ± 12.4 |
| Age Part B | — | — | 57.3 ± 10.3 | 58.1 ± 13.7 | 54.0 ± 11.9 | 56.4 ± 12.0 |
| Sex: Female, Male(Participants) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 14 | 18 | 14 | 21 | 69 |
| Male | 5 | 3 | 14 | 17 | 12 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 6 | 8 | 10 | 31 |
| Not Hispanic or Latino | 5 | 12 | 26 | 23 | 23 | 89 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 3 | 2 | 1 | 7 |
| White | 7 | 16 | 29 | 26 | 31 | 109 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 3 | 0 | 3 |
| Height(cm) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| Height Part A | 169.0 ± 7.4 | 163.2 ± 9.9 | — | — | — | 164.9 ± 9.5 |
| Height Part B | — | — | 168.1 ± 9.8 | 167.1 ± 8.5 | 166.8 ± 10.1 | 167.3 ± 9.4 |
| Weight(kg) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| Weight Part A | 112.4 ± 32.6 | 103.4 ± 25.4 | — | — | — | 106.0 ± 27.3 |
| Weight Part B | — | — | 97.5 ± 18.3 | 95.8 ± 14.0 | 98.8 ± 18.4 | 97.4 ± 16.9 |
| BMI(kg/m^2) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| BMI Part A | 39.3 ± 10.2 | 38.8 ± 9.0 | — | — | — | 38.9 ± 9.1 |
| BMI Part B | — | — | 34.3 ± 4.3 | 34.3 ± 4.1 | 35.4 ± 5.1 | 34.7 ± 4.5 |
| Waist circumference(cm) | Placebo Part A | Vonafexor Pooled Part A | Placebo Part B | Vonafexor 100 mg QD Part B | Vonafexor 200 mg QD Part B | Total |
|---|---|---|---|---|---|---|
| Waist circumference Part A | 128.9 ± 31.5 | 116.1 ± 16.0 | — | — | — | 119.8 ± 21.7 |
| Waist circumference Part B | — | — | 112.6 ± 13.0 | 111.4 ± 8.6 | 114.1 ± 11.8 | 112.7 ± 11.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Jun 2021, 28 months.
Results were first posted in May 2023, 1 year 10 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 28 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Enyo Pharma